Provided exclusively by Mergermarket
Pfizer (NYSE: PFE), the drug maker based in New York, is considering selling multiple drugs for cardiology, urology, and beyond with the help of JP Morgan as advisor, according to a newswire report.
The Bloomberg item, citing people familiar with the matter, said the potential divestitures could fetch up to USD 2bn from a buyer and that the company’s preference would be to sell the treatments as a single portfolio.
The report credited the people with stating that the products could appeal to either private equity firms or drugmakers, and that their combined revenue of USD 700m is 40% derived from US sales and 45% from sales in Europe.
Both Pfizer and JPMorgan declined to comment.
As seen in the mergermarket newsletter on 02/02/2017